Hold
-
Financial
Histogenics Corp Stock Rating Lowered by Zacks (HSGX)
By Karim Khaledi Histogenics Corp (NASDAQ:HSGX) was downgraded by Zacks from a “hold” rating to a “sell” rating in a report released on…
Read More » -
Financial
Analysts Set CONMED Target Price at $53.60 (NASDAQ:CNMD)
By Jim Brewer CONMED (NASDAQ:CNMD) has received a consensus recommendation of “Hold” from the seven brokerages that are presently covering the stock, StockRatingsNetwork reports.…
Read More » -
Financial
Ladenburg Thalmann Lowers CONMED to Neutral (CNMD)
Ladenburg Thalmann cut shares of CONMED (NASDAQ:CNMD) from a buy rating to a neutral rating in a research note issued to investors…
Read More »